RxSympazan - clobazam oral film CIV, Assertio, Lake Forest, IL (2026)

04/23/2026

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚: https://bit.ly/SYMPAZAN

We’re excited to announce our participation in Epilepsy Awareness Day at Disney World on April 25-26. Visit us at Booth 413. We look forward to seeing you there!

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2026 Otter Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Otter Pharmaceuticals, LLC.

04/06/2026

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗮𝗻𝗱 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗱𝗼𝗰𝘁𝗼𝗿: https://bit.ly/SYMPAZAN

RxSympazan - clobazam oral film CIV does not require food or water, preparation, and can be used on the go.

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2026 Otter Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Otter Pharmaceuticals, LLC.APL-SYM-0068 Aug. 2024

03/27/2026

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚:
https://bit.ly/SYMPAZAN

The SYMPAZAN website contains resources and data intended to support prescribing needs.

Visit the website to access this information:
https://www.sympazan.com/

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2026 Otter Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Otter Pharmaceuticals, LLC.

03/19/2026

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗮𝗻𝗱 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗱𝗼𝗰𝘁𝗼𝗿: https://bit.ly/SYMPAZAN

RxSympazan - clobazam oral film CIV

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2026 Otter Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Otter Pharmaceuticals, LLC.

02/25/2026

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗮𝗻𝗱 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗱𝗼𝗰𝘁𝗼𝗿: https://bit.ly/SYMPAZAN

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2026 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals. APL-SYM-0067 Aug. 2024

12/21/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗮𝗻𝗱 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗱𝗼𝗰𝘁𝗼𝗿: https://bit.ly/SYMPAZAN

Each SYMPAZAN oral film comes in a child-resistant pouch and is designed for ease of administration. Review the "Instructions for Use" video for complete guidance on how to properly open and administer SYMPAZAN.

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

12/10/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚: https://bit.ly/SYMPAZAN

We are thrilled to have participated in the AES Annual Meeting hosted in Atlanta, GA. We look forward to seeing you next year!

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

12/05/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚: https://bit.ly/SYMPAZAN

We’re excited to announce our participation in the upcoming AES Annual Meeting from December 5–9. We look forward to seeing you there!

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

11/12/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚: https://bit.ly/SYMPAZAN

We are thrilled to have participated in Epilepsy Awareness Day & Expo hosted in Anaheim, CA from November 10–12. We'll see you next year!

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

11/09/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚: https://bit.ly/SYMPAZAN

We’re excited to announce our participation in Epilepsy Awareness Day & Expo, taking place November 10–12 in Anaheim, CA. We look forward to seeing you there!

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

11/02/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗮𝗻𝗱 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗱𝗼𝗰𝘁𝗼𝗿: https://bit.ly/SYMPAZAN

November is Epilepsy Awareness Month. We are committed to supporting initiatives that raise awareness and provide resources for individuals living with epilepsy.

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

11/01/2025

𝗣𝗹𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗰𝗸 𝗵𝗲𝗿𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝗰𝗿𝗶𝗯𝗶𝗻𝗴 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗕𝗢𝗫𝗘𝗗 𝗪𝗔𝗥𝗡𝗜𝗡𝗚 𝗮𝗻𝗱 𝘁𝗮𝗹𝗸 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗱𝗼𝗰𝘁𝗼𝗿: https://bit.ly/SYMPAZAN

Today is International LGS Awareness Day. We recognize the work of the LGS Foundation in advancing awareness and support for those affected by Lennox-Gastaut Syndrome.

SELECT IMPORTANT SAFETY INFORMATION

𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗶𝘀 𝗮 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 𝗧𝗮𝗸𝗶𝗻𝗴 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗼𝗽𝗶𝗼𝗶𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗮𝗹𝗰𝗼𝗵𝗼𝗹, 𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗰𝗲𝗻𝘁𝗿𝗮𝗹 𝗻𝗲𝗿𝘃𝗼𝘂𝘀 𝘀𝘆𝘀𝘁𝗲𝗺 (𝗖𝗡𝗦) 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗮𝗻𝘁𝘀 (𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘀𝘁𝗿𝗲𝗲𝘁 𝗱𝗿𝘂𝗴𝘀) 𝗰𝗮𝗻 𝗰𝗮𝘂𝘀𝗲 𝘀𝗲𝘃𝗲𝗿𝗲 𝗱𝗿𝗼𝘄𝘀𝗶𝗻𝗲𝘀𝘀, 𝗯𝗿𝗲𝗮𝘁𝗵𝗶𝗻𝗴 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 (𝗿𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆 𝗱𝗲𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻), 𝗰𝗼𝗺𝗮, 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗥𝗶𝘀𝗸 𝗼𝗳 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻. 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗿𝗶𝘀𝗸 𝗳𝗼𝗿 𝗮𝗯𝘂𝘀𝗲, 𝗺𝗶𝘀𝘂𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗱𝗱𝗶𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗯𝗲𝗻𝘇𝗼𝗱𝗶𝗮𝘇𝗲𝗽𝗶𝗻𝗲𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗹𝗲𝗮𝗱 𝘁𝗼 𝗼𝘃𝗲𝗿𝗱𝗼𝘀𝗲 𝗮𝗻𝗱 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗮 𝗮𝗻𝗱 𝗱𝗲𝗮𝘁𝗵.

𝗔𝗯𝗿𝘂𝗽𝘁 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗿𝗮𝗽𝗶𝗱 𝗱𝗼𝘀𝗮𝗴𝗲 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡 𝗮𝗳𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘂𝘀𝗲 𝗺𝗮𝘆 𝗽𝗿𝗲𝗰𝗶𝗽𝗶𝘁𝗮𝘁𝗲 𝗮𝗰𝘂𝘁𝗲 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘄𝗵𝗶𝗰𝗵 𝗰𝗮𝗻 𝗯𝗲 𝗹𝗶𝗳𝗲-𝘁𝗵𝗿𝗲𝗮𝘁𝗲𝗻𝗶𝗻𝗴. 𝗧𝗼 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝗿𝗶𝘀𝗸 𝗼𝗳 𝘄𝗶𝘁𝗵𝗱𝗿𝗮𝘄𝗮𝗹 𝗿𝗲𝗮𝗰𝘁𝗶𝗼𝗻𝘀, 𝘂𝘀𝗲 𝗮 𝗴𝗿𝗮𝗱𝘂𝗮𝗹 𝘁𝗮𝗽𝗲𝗿 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲 𝗦𝗬𝗠𝗣𝗔𝗭𝗔𝗡.

Please see additional Important Safety Information athttp://sympazan.com/pdfs/pi.pdf

© 2025 Assertio Specialty Pharmaceuticals. A subsidiary of Assertio Holdings, Inc. All rights reserved. Sympazan is a registered trademark licensed by Assertio Specialty Pharmaceuticals.

RxSympazan - clobazam oral film CIV

04/23/2026

04/06/2026

03/27/2026

03/19/2026

02/25/2026

12/21/2025

12/10/2025

12/05/2025

11/12/2025

11/09/2025

11/02/2025

11/01/2025

Address

Website

Services

Specialties

Alerts

Shortcuts

Share

Category